We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
MEI Pharma Inc | NASDAQ:MEIP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.06 | 3.00 | 3.86 | 3.21 | 3.06 | 3.13 | 17,147 | 01:00:00 |
SAN DIEGO, Feb. 8, 2018 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today reported results for its second quarter ended December 31, 2017.
"We continue to build on the progress we reported last quarter with important advances in the clinical development programs across our pipeline," said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. "Already in 2018, the Food and Drug Administration cleared the Investigational New Drug Application for voruciclib, and pracinostat was awarded Orphan Drug Designation from the European Medicines Agency for the treatment of acute myeloid leukemia."
Dr. Gold added: "In the coming months we look forward to separate data readouts in three programs: pracinostat's stage 1 of a Phase 2 dose-optimization study in myelodysplastic syndrome (MDS); ME-401's single agent safety and efficacy in relapsed/refractory chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL); and ME-344's interim results from a proof-of-concept study in combination with bevacizumab (marketed as Avastin®) in human epidermal growth factor receptor 2 (HER2) negative breast cancer. In addition, we look forward to the initiation of our Phase 1 single-agent study with voruciclib in relapsed/refractory B lymphocyte malignancies."
Recent Program Highlights
Pracinostat
MEI-401
Voruciclib
Upcoming Milestones
Pracinostat
ME-401
Voruciclib
ME-344
Financial Highlights
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes pracinostat, an oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA. Pracinostat has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for use in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Pracinostat is also being developed in combination with azacitidine for the treatment of patients with high and very high-risk myelodysplastic syndrome (MDS). MEI Pharma's clinical development pipeline also includes ME-401, a highly differentiated oral PI3K delta inhibitor currently in a Phase 1b study in patients with relapsed/refractory CLL or follicular lymphoma, and voruciclib, an oral, selective CDK inhibitor shown to suppress MCL1, a known mechanism of resistance to BCL2 inhibitors. The Company is also developing ME-344, a novel mitochondrial inhibitor currently in an investigator-sponsored study in combination with bevacizumab for the treatment of HER2-negative breast cancer. Pracinostat, ME-401, ME-344 and voruciclib are investigational agents and are not approved for use in the U.S. For more information, please visit www.meipharma.com.
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
MEI PHARMA, INC. | |||
CONDENSED BALANCE SHEETS | |||
(In thousands, except per share amounts) | |||
December 31, |
June 30, | ||
2017 |
2017 | ||
(unaudited) |
|||
ASSETS | |||
Current assets: |
|||
Cash and cash equivalents |
$ 7,339 |
$ 8,458 | |
Short term investments |
35,102 |
45,107 | |
Total cash, cash equivalents and short-term investments |
42,441 |
53,565 | |
Prepaid expenses and other current assets |
772 |
1,758 | |
Total current assets |
43,213 |
55,323 | |
Intangible assets, net |
314 |
331 | |
Property and equipment, net |
40 |
50 | |
Total assets |
$ 43,567 |
$ 55,704 | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |||
Current liabilities: |
|||
Accounts payable |
$ 1,089 |
$ 585 | |
Accrued liabilities |
3,230 |
3,285 | |
Deferred revenues |
890 |
996 | |
Total current liabilities |
5,209 |
4,866 | |
Commitments and contingencies (Note 5) |
|||
Stockholders' equity: |
|||
Preferred stock, $0.01 par value; 100 shares authorized; none outstanding |
- |
- | |
Common stock, $0.00000002 par value; 113,000 shares authorized; 37,052 and 36,772 shares issued and outstanding at December 31, 2017 and June 30, 2017, respectively |
- |
- | |
Additional paid-in-capital |
227,556 |
225,169 | |
Accumulated deficit |
(189,198) |
(174,331) | |
Total stockholders' equity |
38,358 |
50,838 | |
Total liabilities and stockholders' equity |
$ 43,567 |
$ 55,704 | |
MEI PHARMA, INC. | |||||||
CONDENSED STATEMENTS OF OPERATIONS | |||||||
(In thousands, except per share amounts) | |||||||
(Unaudited) | |||||||
Three Months Ended |
Six Months Ended | ||||||
2017 |
2016 |
2017 |
2016 | ||||
Revenues: |
|||||||
License revenue |
$ - |
$ 17,101 |
$ - |
$ 17,101 | |||
Research and development revenue |
358 |
98 |
641 |
1,194 | |||
Total revenues |
358 |
17,199 |
641 |
18,295 | |||
Operating expenses: |
|||||||
Cost of research and development revenue |
728 |
1,771 |
1,346 |
2,865 | |||
Research and development |
3,444 |
1,642 |
9,508 |
3,288 | |||
General and administrative |
2,358 |
1,970 |
4,846 |
4,650 | |||
Total operating expenses |
6,530 |
5,383 |
15,700 |
10,803 | |||
(Loss) income from operations |
(6,172) |
11,816 |
(15,059) |
7,492 | |||
Other income (expense): |
|||||||
Interest and dividend income |
93 |
69 |
193 |
124 | |||
Income tax expense |
- |
- |
(1) |
(1) | |||
Net (loss) income |
$ (6,079) |
$ 11,885 |
$ (14,867) |
$ 7,615 | |||
Net (loss) income per share, basic |
$ (0.16) |
$ 0.32 |
$ (0.40) |
$ 0.21 | |||
Net (loss) income per share, diluted |
$ (0.16) |
$ 0.32 |
$ (0.40) |
$ 0.21 | |||
Shares used in computing net (loss) income per share: |
|||||||
Basic |
37,414 |
37,172 |
37,390 |
36,460 | |||
Diluted |
37,414 |
37,217 |
37,390 |
36,501 | |||
View original content with multimedia:http://www.prnewswire.com/news-releases/mei-pharma-reports-second-quarter-fiscal-year-2018-results-300595603.html
SOURCE MEI Pharma, Inc.
Copyright 2018 PR Newswire
1 Year MEI Pharma Chart |
1 Month MEI Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions